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Abstract
Tyrosine hydroxylase deficiency is a rare autosomal recessive, treatable disorder of
neurotransmission. Fewer than 100 cases have been reported so far. We present a
case of a 10-month-old infant who was symptomatic since 5 months of age and
who received an initial diagnosis of infantile tremor syndrome. She presented with
rest tremor, decreased facial expression, global hypokinesia, and later on with
oculogyric crisis and dystonia. This diagnosis was revised after confirmation of
tyrosine hydroxylase deficiency by CSF neurotransmitter analysis. Genetic studies
revealed one previously reported missense variant, p.Thr399Met, and another large
deletion starting upstream of exon 1 and encompassing exon 1. She was started on
treatment with escalating doses of L-Dopa/Carbidopa, with folinic acid supplemen-
tation. At 3.5 years of age, her cognitive functioning and development is appropri-
ate for age. There is complete subsidence of dystonia and oculogyric episodes. She
has occasional chorieform movements which appear to be drug related.
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1 | INTRODUCTION
Tyrosine hydroxylase (TH) deficiency (OMIM ♯605407;
encoded by the TH gene OMIM *191290) is an autosomal
recessive disorder of L-Dopa biosynthesis, the rate-
limiting step for the generation of the catecholamine neu-
rotransmitters dopamine, norepinephrine, and epineph-
rine.1 This monoamine neurotransmitter disorder, also
known as autosomal recessive Segawa syndrome, has a
broad continuous spectrum, manifesting from infancy to
young adulthood as abnormal movements in the form of
dystonia, rest tremor and Parkinsonism. There are three
types of TH deficiency, based on severity of symptoms
and responsiveness to L-Dopa. There is a wide spectrum
of the disorder. These are Type (1) TH-deficient L-Dopa-
responsive dystonia (the mild form of TH deficiency),
(2) TH-deficient infantile Parkinsonism with motor delay
(the severe form), and (3) TH-deficient progressive infan-
tile encephalopathy.2 Up to date, fewer than 100 patients
have been published in literature, including one from
India.1,3-5 We present a case of an infant girl with TH-
deficient infantile Parkinsonism and motor delay, with
one previously described pathogenic variant and another
hitherto unreported large deletion in the TH gene.
2 | CASE REPORT
A 10-month-old infant girl, born to nonconsanguineous
parents, presented with a history of progressive abnormal
movements of body along with a global developmental
delay noted since 5 months of age.
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Her antenatal period had been uneventful, with nor-
mal fetal movements perceived by her mother. She was
born via Caesarean section, with birth weight of 3 kg and
cried immediately. She was noted to be hypotonic from
neonatal period, but did not require admission. At
5-months of age, she was noted to have rest tremor
(Video S1), decreased facial expression, global hyp-
okinesia, and abnormal stiffening of body especially dur-
ing crying spells. She had attained some personal social
milestones like social smile and could make noises, but
had significant motor delay. There was no history of sei-
zures. Her anthropometry showed a weight and length
below third centile, while head circumference was 42 cm
at 50th centile.
A metabolic workup including plasma lactate, ammo-
nia, dried blood spot acyl carnitines, aminoacids, and uri-
nary organic acids—did not show any abnormality,
except for mild elevation of lactate. As mild nutritional
Vitamin B12 deficiency had been identified, she was
treated initially as infantile tremor syndrome with Vita-
min B12 supplementation, but this did not show any ben-
efit. Over next few months the hypokinesia, rest tremor
and episodic dystonia had worsened. She also started to
have prolonged periods of oculogyria, especially in eve-
nings (Video S2). Serum prolactin was elevated
(35.76 ng/mL; normal <24 ng/mL). Hence, a biosynthesis
defect for catecholamine neurotransmitter was consid-
ered, including evaluation of monoamine neurotransmit-
ter metabolites in the cerebrospinal fluid (CSF) and
genetic testing of genomic DNA.
CSF studies revealed low levels of homovanillic acid
(HVA, 62 nmoL/L; normal range 295-932 for 0.5-1 year age
group) as well as 3-methoxy-4-hydroxyphenylglycol (MHPG,
9.8 nmoL/L; normal range 51-112 for 0.5-1 year age group),
while other metabolites were at normal levels (eg,
5-hydroxyindolacetic acid {HIAA} and 5-hydroxytryptophan).
The CSF HVA:HIAA ratio was 0.3 (normal range 1.5-3.5).
CSF pterins and folates were in the normal range. These find-
ings were compatible with diagnosis of TH deficiency. Based
on these findings, the subject was treated, commencing at
11 months of age, with a starting dose of L-Dopa/Carbidopa
(4:1 ratio at 0.5 mg/kg/day) that was gradually increased over
months to reach 6 mg/kg/day. After few months, a repeat
CSF analysis was performed for monoamine neurotransmit-
ter metabolites, which showed levels of HVA and MHPG in
the normal range, but a low folate (5-methyltetrahydrofolic
acid). Folinic acid was started at 1 mg/kg/day and the child
showed good in form of significantly improved facial expres-
sion with motor and cognitive progress.
On follow up, the child showed a significant motor
recovery (Video S3). At 3.5 years of age, she is ambulant
including can run and climb stairs without support. Cog-
nitively, she is normal and is performing appropriately
for her academic level. The episodic dystonia and
SYNOPSIS
Early diagnosis even of a severe TH deficiency
leads to better outcome.
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FIGURE 1 Diagram showing
the evidence and extent of large
deletion noted in TH gene in
heterozygous state. Identification of
the novel deletion allele c.-
2188_103-194del in the TH gene that
extends over 3,011 bp and includes
the entire exon 1. A, Schematic of
the deletion showing the 50 portion
of the human TH gene, including
exons 1 and 2. B, Lower part:
Agarose gel-separation of long-range
PCR products using flanking primers
(not shown). Upper part: result of
Sanger sequencing of the “deletion
fragment,” revealing the molecular
details of the DNA-breakpoint
(RefSeq NG_008128.1)
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oculogyria has subsided completely. She now has normal
facial expression. She does have choreiform movements
which appear to be related to the prolonged use of L-
Dopa, to which she has responded well on addition of
amantadine at dose of 5 mg/kg/day. These movements
are not affecting her daily routine function or quality of
life (video in pre-treatment and post-treatment state
provided).
Molecular testing was performed by next generation
sequencing using an Illumina MiSeq device to sequence
the coding exons and flanking introns from a defined
panel of genes, including the TH gene (reference
sequence ENSG00000180176, NM_199292.2; subpanel
“infantile parkinson dystonia”; more details can be
obtained by contacting the authors). This analysis rev-
ealed the following variants in the TH gene. One hetero-
zygous single nucleotide missense variant, previously
reported as likely pathogenic in exon 11 (c.1196C>T; p.
Thr399Met) (www.ncbi.nlm.nih.gov/clinvar),6 and
another homozygous variant in exon 1 (c.16G>A; p.
Ala6Thr) which was likely not to be pathogenic. The vari-
ants were further tested in parents using the Sanger
sequencing method. It was noted that while both the var-
iants were present in heterozygous form in the mother,
none of these variants were present in the father. This
was interpreted that both variants were inherited in cis-
form from the mother, and the father was suspected to be
harboring a deletion involving exon 1, since the exon
1 variant was observed in apparent homozygous form in
the child. Further analyses, including long-rang PCR,
revealed a novel deletion involving exon 1, c.-
2188_103-194del that was present in a heterozygous state
in the child's DNA (Figure 1). Furthermore, the father of
child was noted to carry the same variant in heterozygous
state. Thus, the detection of these two compound hetero-
zygote variants in the TH gene, c.1196C>T;p.Thr399Met
and 3011 base pair deletion (c.-2188_103-194del) con-
firmed the diagnosis of TH deficiency.
3 | DISCUSSION
TH deficiency is a treatable disorder, if recognized early
in the disease course. Because of the rarity, the awareness
of this condition is less especially amongst Pediatricians
and general physicians. The present case was initially
thought to be a vitamin B12-deficiency related infantile
tremor syndrome, but was further investigated after no
response to vitamin B12 was noted. The infantile tremor
syndrome is a well-known entity in the Indian scenario,
even today.7 The present case was confirmed to have
TH deficiency only after definitive neurotransmitter
analysis and genetic testing. Our case showed clinical
presentation consistent with type 2 TH deficiency, with
severe infantile Parkinsonism-like symptoms. She dem-
onstrated a good clinical improvement upon therapy fol-
lowing a timely diagnosis. A secondary cerebral folate
deficiency was treated leading to better prognosis. There
is evidence in another neurotransmitter disorder (AADC
deficiency) that secondary cerebral folate deficiency can
develop with L-dopa therapy—O-methylation of the
excessive amounts of L-Dopa to 3-OMD depletes methyl
donors including SAM and 5-MTHF.8
Severe infantile Parkinsonism type of TH deficiency
has been scarcely reported with fewer than 100 cases
reported till date.2 In one study from India, two siblings
were described presenting similar to our case and show-
ing improvement upon early treatment.3 The molecular
studies in the two infants revealed compound heterozy-
gous variants, one of them being a common, p.Arg233His
in exon 6 of TH gene. Our patient harbored another pre-
viously reported variant, p.Tyr399Met along with a novel
large deletion encompassing exon 1 in TH gene. The vari-
ant, p.Tyr399Met has been studied previously in a
16-week-old human fetus revealing a decreased expres-
sion in TH and in dopaminergic proteins in the fetal
brain.9 This variant was described in the sibling of the
fetus who presented at 3 years of age and showed a
severe phenotype at 17 years of age. The second vari-
ant in our case was a novel large deletion and is only
the second report of a large deletion in TH gene. The
previous deletion reported spanned from intron 11 to
the 30end in exon 13, encompassing a segment of
716 bp (c.1197 + 25_1391del) including exon 12 and
part of exon 13.10 The deletion observed in our case
involved region of TH gene 50 of exon 1 up to a part of
exon 1(c.-2188_103-194del). There is another report of
a novel deletion of entire TH gene in an adult with
Parkinson disease.11 This was a heterozygous whole
gene deletion in a 59-year-old woman who presented
with symptoms of PD at age 54 years, and who was
responsive to L-Dopa. A genotype phenotype correla-
tion is difficult to establish as all cases with a deletion,
including ours, have been in heterozygous states,
observed either alone or along with a different point
mutation. In our case, the reported variant is associ-
ated with a severe phenotype.9
The case presented highlights the importance of keen
clinical observation, appropriate and timely biochemical
investigations (CSF neurotransmitters, supported by a
high prolactin level) to achieve an accurate diagnosis.
Genetic testing can be challenging, as a large deletion
was not expected and was detected ingeniously using
innovative molecular methods. A timely initiation of
appropriate therapy has led to a good outcome in the oth-
erwise severe disorder.
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In conclusion, it is appropriate to mention that in cases
with negative results on Next Generation Sequencing tech-
nique, or if only one heterozygous variant is found in TH
gene and if clinical suspicion is high, deletion analysis by
other molecular or cytogenetic techniques is warranted.
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